{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,29]],"date-time":"2026-06-29T18:20:49Z","timestamp":1782757249144,"version":"3.54.5"},"reference-count":49,"publisher":"Elsevier BV","issue":"32","license":[{"start":{"date-parts":[[2020,7,1]],"date-time":"2020-07-01T00:00:00Z","timestamp":1593561600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,7,1]],"date-time":"2020-07-01T00:00:00Z","timestamp":1593561600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100000272","name":"National Institute for Health Research","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000272","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000265","name":"Medical Research Council","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000265","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100013373","name":"NIHR Oxford Biomedical Research Centre","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100013373","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Vaccine"],"published-print":{"date-parts":[[2020,7]]},"DOI":"10.1016\/j.vaccine.2020.05.042","type":"journal-article","created":{"date-parts":[[2020,6,9]],"date-time":"2020-06-09T09:09:40Z","timestamp":1591693780000},"page":"5036-5048","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":16,"title":["Viral vectored hepatitis C virus vaccines generate pan-genotypic T cell responses to conserved subdominant epitopes"],"prefix":"10.1016","volume":"38","author":[{"given":"Timothy","family":"Donnison","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Annette","family":"von Delft","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anthony","family":"Brown","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leo","family":"Swadling","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claire","family":"Hutchings","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tom\u00e1\u0161","family":"Hanke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Senthil","family":"Chinnakannan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eleanor","family":"Barnes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.vaccine.2020.05.042_b0005","unstructured":"World Health Organisation. Global hepatitis report 2017 [Internet]; 2017 [cited 2019 Mar 4]."},{"issue":"s1","key":"10.1016\/j.vaccine.2020.05.042_b0010","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1111\/liv.12423","article-title":"HCV direct-acting antiviral agents: the best interferon-free combinations","volume":"34","author":"Schinazi","year":"2014","journal-title":"Liver Int"},{"issue":"3","key":"10.1016\/j.vaccine.2020.05.042_b0015","doi-asserted-by":"crossref","DOI":"10.1053\/j.gastro.2014.05.010","article-title":"Detection of a sexually transmitted hepatitis C virus protease inhibitor-resistance variant in a human immunodeficiency virus-infected homosexual man","volume":"147","author":"Franco","year":"2014","journal-title":"Gastroenterology"},{"issue":"4","key":"10.1016\/j.vaccine.2020.05.042_b0020","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1016\/j.jhep.2016.06.015","article-title":"Early occurrence and recurrence of hepatocellular carcinoma in HCV-related cirrhosis treated with direct-acting antivirals","volume":"65","author":"Conti","year":"2016","journal-title":"J Hepatol"},{"issue":"1","key":"10.1016\/j.vaccine.2020.05.042_b0025","doi-asserted-by":"crossref","first-page":"S33","DOI":"10.1016\/j.jhep.2016.07.012","article-title":"HCV epidemiology in high-risk groups and the risk of reinfection","volume":"65","author":"Midgard","year":"2016","journal-title":"J Hepatol"},{"issue":"1","key":"10.1016\/j.vaccine.2020.05.042_b0030","doi-asserted-by":"crossref","DOI":"10.1186\/s12916-015-0440-2","article-title":"The role of a hepatitis C virus vaccine: modelling the benefits alongside direct-acting antiviral treatments","volume":"13","author":"Scott","year":"2015","journal-title":"BMC Med"},{"issue":"3","key":"10.1016\/j.vaccine.2020.05.042_b0035","doi-asserted-by":"crossref","first-page":"924","DOI":"10.1053\/j.gastro.2004.06.015","article-title":"High resolution analysis of cellular immune responses in resolved and persistent hepatitis C virus infection","volume":"127","author":"Lauer","year":"2004","journal-title":"Gastroenterology"},{"issue":"9","key":"10.1016\/j.vaccine.2020.05.042_b0040","doi-asserted-by":"crossref","first-page":"2479","DOI":"10.1002\/1521-4141(200009)30:9<2479::AID-IMMU2479>3.0.CO;2-B","article-title":"CD8+ T lymphocyte responses are induced during acute hepatitis C virus infection but are not sustained","volume":"30","author":"Lechner","year":"2000","journal-title":"Eur J Immunol"},{"issue":"4","key":"10.1016\/j.vaccine.2020.05.042_b0045","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1016\/S1074-7613(00)80044-8","article-title":"Analysis of a successful immune response against hepatitis C virus","volume":"10","author":"Cooper","year":"1999","journal-title":"Immunity"},{"issue":"10","key":"10.1016\/j.vaccine.2020.05.042_b0050","doi-asserted-by":"crossref","first-page":"1395","DOI":"10.1084\/jem.194.10.1395","article-title":"Determinants of viral clearance and persistence during acute hepatitis C virus infection","volume":"194","author":"Thimme","year":"2001","journal-title":"J Exp Med"},{"issue":"4","key":"10.1016\/j.vaccine.2020.05.042_b0055","doi-asserted-by":"crossref","first-page":"933","DOI":"10.1016\/S0016-5085(99)70353-7","article-title":"Recurrence of hepatitis C virus after loss of virus-specific CD4+ T-cell response in acute hepatitis C","volume":"117","author":"Gerlach","year":"1999","journal-title":"Gastroenterology"},{"issue":"24","key":"10.1016\/j.vaccine.2020.05.042_b0060","doi-asserted-by":"crossref","first-page":"12584","DOI":"10.1128\/JVI.76.24.12584-12595.2002","article-title":"Broad specificity of virus-specific CD4+ T-helper-cell responses in resolved hepatitis C virus infection","volume":"76","author":"Day","year":"2002","journal-title":"J Virol"},{"key":"10.1016\/j.vaccine.2020.05.042_b0065","doi-asserted-by":"crossref","unstructured":"Klenerman P, Thimme R. T cell responses in hepatitis C: the good, the bad and the unconventional. 2011.","DOI":"10.1136\/gutjnl-2011-300620"},{"key":"10.1016\/j.vaccine.2020.05.042_b0070","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1016\/j.antiviral.2014.11.009","article-title":"T cell responses in hepatitis C virus infection: Historical overview and goals for future research","volume":"114","author":"Holz","year":"2015","journal-title":"Antiviral Res"},{"issue":"7053","key":"10.1016\/j.vaccine.2020.05.042_b0075","doi-asserted-by":"crossref","first-page":"946","DOI":"10.1038\/nature04079","article-title":"Adaptive immune responses in acute and chronic hepatitis C virus infection","volume":"436","author":"Bowen","year":"2005","journal-title":"Nature"},{"issue":"14","key":"10.1016\/j.vaccine.2020.05.042_b0080","doi-asserted-by":"crossref","first-page":"6025","DOI":"10.1073\/pnas.0607026104","article-title":"Rapid induction of virus-neutralizing antibodies and viral clearance in a single-source outbreak of hepatitis C","volume":"104","author":"Pestka","year":"2007","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"10","key":"10.1016\/j.vaccine.2020.05.042_b0085","doi-asserted-by":"crossref","first-page":"6023","DOI":"10.1128\/JVI.79.10.6023-6034.2005","article-title":"Human serum facilitates hepatitis C virus infection, and neutralizing responses inversely correlate with viral replication kinetics at the acute phase of hepatitis C virus infection","volume":"79","author":"Lavillette","year":"2005","journal-title":"J Virol"},{"issue":"1","key":"10.1016\/j.vaccine.2020.05.042_b0090","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1053\/j.gastro.2009.09.017","article-title":"Spontaneous control of primary hepatitis C virus infection and immunity against persistent reinfection","volume":"138","author":"Osburn","year":"2010","journal-title":"Gastroenterology"},{"issue":"11","key":"10.1016\/j.vaccine.2020.05.042_b0095","doi-asserted-by":"crossref","first-page":"1563","DOI":"10.1136\/gut.2010.228403","article-title":"Molecular footprints reveal the impact of the protective HLA-A*03 allele in hepatitis C virus infection","volume":"60","author":"Fitzmaurice","year":"2011","journal-title":"Gut"},{"issue":"1","key":"10.1016\/j.vaccine.2020.05.042_b0100","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1002\/hep.23275","article-title":"Protective effect of human leukocyte antigen B27 in hepatitis C virus infection requires the presence of a genotype-specific immunodominant CD8+ T-cell epitope","volume":"51","author":"Neumann-Haefelin","year":"2010","journal-title":"Hepatology"},{"issue":"2","key":"10.1016\/j.vaccine.2020.05.042_b0105","doi-asserted-by":"crossref","DOI":"10.1053\/j.gastro.2010.09.042","article-title":"Spontaneous control of HCV is associated with expression of HLA-B 57 and preservation of targeted epitopes","volume":"140","author":"Kim","year":"2011","journal-title":"Gastroenterology"},{"issue":"4","key":"10.1016\/j.vaccine.2020.05.042_b0110","doi-asserted-by":"crossref","first-page":"235","DOI":"10.7326\/0003-4819-158-4-201302190-00003","article-title":"Genome-wide association study of spontaneous resolution of hepatitis C virus infection: data from multiple cohorts","volume":"158","author":"Duggal","year":"2013","journal-title":"Ann Intern Med"},{"issue":"12","key":"10.1016\/j.vaccine.2020.05.042_b0115","doi-asserted-by":"crossref","first-page":"1645","DOI":"10.1084\/jem.20030239","article-title":"Memory CD8+ T cells are required for protection from persistent hepatitis C virus infection","volume":"197","author":"Shoukry","year":"2003","journal-title":"J Exp Med"},{"issue":"5645","key":"10.1016\/j.vaccine.2020.05.042_b0120","doi-asserted-by":"crossref","DOI":"10.1126\/science.1088774","article-title":"HCV persistence and immune evasion in the absence of memory T cell help","volume":"302","author":"Grakoui","year":"2003","journal-title":"Science (80-.)"},{"issue":"1","key":"10.1016\/j.vaccine.2020.05.042_b0125","doi-asserted-by":"crossref","first-page":"1113","DOI":"10.1038\/s41467-019-09105-0","article-title":"Vaccination to prevent T cell subversion can protect against persistent hepacivirus infection","volume":"10","author":"Hartlage","year":"2019","journal-title":"Nat Commun"},{"issue":"261","key":"10.1016\/j.vaccine.2020.05.042_b0130","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.3009185","article-title":"A human vaccine strategy based on chimpanzee adenoviral and MVA vectors that primes, boosts, and sustains functional HCV-specific T cell memory","volume":"6","author":"Swadling","year":"2014","journal-title":"Sci Transl Med"},{"key":"10.1016\/j.vaccine.2020.05.042_b0135","unstructured":"National Institutes of Health. Trial evaluating experimental hepatitis C vaccine concludes [Internet]. Press Release; 2019."},{"issue":"1","key":"10.1016\/j.vaccine.2020.05.042_b0140","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1002\/hep.26744","article-title":"Expanded classification of hepatitis C virus into 7 genotypes and 67 subtypes: updated criteria and genotype assignment web resource","volume":"59","author":"Smith","year":"2014","journal-title":"Hepatology"},{"issue":"1","key":"10.1016\/j.vaccine.2020.05.042_b0145","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1002\/eji.201444686","article-title":"Cross-reactivity of hepatitis C virus specific vaccine-induced T cells at immunodominant epitopes","volume":"45","author":"Kelly","year":"2015","journal-title":"Eur J Immunol"},{"key":"10.1016\/j.vaccine.2020.05.042_b0150","article-title":"The broad assessment of HCV genotypes 1 and 3 antigenic targets reveals limited cross-reactivity with implications for vaccine design","author":"von Delft","year":"2015","journal-title":"Gut"},{"issue":"1","key":"10.1016\/j.vaccine.2020.05.042_b0155","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1002\/hep.27259","article-title":"Global distribution and prevalence of hepatitis C virus genotypes","volume":"61","author":"Messina","year":"2014","journal-title":"Hepatology"},{"issue":"1","key":"10.1016\/j.vaccine.2020.05.042_b0160","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1007\/s00430-014-0372-z","article-title":"Mutational escape of CD8+ T cell epitopes: implications for prevention and therapy of persistent hepatitis virus infections","volume":"204","author":"Timm","year":"2015","journal-title":"Med Microbiol Immunol"},{"issue":"2","key":"10.1016\/j.vaccine.2020.05.042_b0165","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1016\/j.vaccine.2017.10.079","article-title":"The generation of a simian adenoviral vectored HCV vaccine encoding genetically conserved gene segments to target multiple HCV genotypes","volume":"36","author":"von Delft","year":"2018","journal-title":"Vaccine"},{"issue":"1","key":"10.1016\/j.vaccine.2020.05.042_b0170","doi-asserted-by":"crossref","first-page":"15020","DOI":"10.1038\/s41598-018-33375-1","article-title":"Development of a molecular adjuvant to enhance antigen-specific CD8+ T cell responses","volume":"8","author":"Halbroth","year":"2018","journal-title":"Sci Rep"},{"issue":"5","key":"10.1016\/j.vaccine.2020.05.042_b0175","doi-asserted-by":"crossref","first-page":"1039","DOI":"10.1038\/mt.2014.15","article-title":"Fusion of HCV nonstructural antigen to MHC class II-associated invariant chain enhances T-cell responses induced by vectored vaccines in nonhuman primates","volume":"22","author":"Capone","year":"2014","journal-title":"Mol Ther"},{"key":"10.1016\/j.vaccine.2020.05.042_b0180","unstructured":"Ondondo B, Abdul-Jawad S, Roshorm Y, Bridgeman A, Hanke T. Vector delivery-dependant effect of human tissue plasminogen activator signal peptide on vaccine induction of T cells; 2016."},{"issue":"115","key":"10.1016\/j.vaccine.2020.05.042_b0185","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.3003155","article-title":"Novel adenovirus-based vaccines induce broad and sustained T cell responses to HCV in man","volume":"4","author":"Barnes","year":"2012","journal-title":"Sci Transl Med"},{"issue":"2","key":"10.1016\/j.vaccine.2020.05.042_b0190","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1038\/nm1353","article-title":"A T-cell HCV vaccine eliciting effective immunity against heterologous virus challenge in chimpanzees","volume":"12","author":"Folgori","year":"2006","journal-title":"Nat Med"},{"issue":"20","key":"10.1016\/j.vaccine.2020.05.042_b0195","doi-asserted-by":"crossref","first-page":"10017","DOI":"10.1128\/JVI.01083-08","article-title":"Early interferon therapy for hepatitis C virus infection rescues polyfunctional, long-lived CD8+ memory T cells","volume":"82","author":"Badr","year":"2008","journal-title":"J Virol"},{"issue":"6","key":"10.1016\/j.vaccine.2020.05.042_b0200","doi-asserted-by":"crossref","first-page":"3603","DOI":"10.4049\/jimmunol.175.6.3603","article-title":"Broad repertoire of the CD4+ Th cell response in spontaneously controlled hepatitis C virus infection includes dominant and highly promiscuous epitopes","volume":"175","author":"Schulze zur Wiesch","year":"2005","journal-title":"J Immunol"},{"issue":"4","key":"10.1016\/j.vaccine.2020.05.042_b0205","doi-asserted-by":"crossref","first-page":"1088","DOI":"10.1002\/hep.510300435","article-title":"Conserved hepatitis C virus sequences are highly immunogenic for CD4(+) T cells: implications for vaccine development","volume":"30","author":"Lamonaca","year":"1999","journal-title":"Hepatology"},{"issue":"11","key":"10.1016\/j.vaccine.2020.05.042_b0210","doi-asserted-by":"crossref","first-page":"1589","DOI":"10.1136\/gutjnl-2011-300650","article-title":"HCV genotype-3a T cell immunity: specificity, function and impact of therapy","volume":"61","author":"Humphreys","year":"2012","journal-title":"Gut"},{"issue":"1","key":"10.1016\/j.vaccine.2020.05.042_b0215","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1002\/hep.20749","article-title":"Comprehensive analyses of CD8+ T cell responses during longitudinal study of acute human hepatitis C","volume":"42","author":"Cox","year":"2005","journal-title":"Hepatology"},{"issue":"1","key":"10.1016\/j.vaccine.2020.05.042_b0220","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1046\/j.1365-2249.2003.02033.x","article-title":"Evidence for lack of cross-genotype protection of CD4+ T cell responses during chronic hepatitis C virus infection","volume":"131","author":"Harcourt","year":"2003","journal-title":"Clin Exp Immunol"},{"key":"10.1016\/j.vaccine.2020.05.042_b0225","doi-asserted-by":"crossref","DOI":"10.1111\/jvh.12874","article-title":"Differential virus-specific CD8 + T-cell epitope repertoire in hepatitis C virus genotype 1 versus 4","author":"Luxenburger","year":"2018","journal-title":"J Viral Hepat"},{"issue":"5","key":"10.1016\/j.vaccine.2020.05.042_b0230","doi-asserted-by":"crossref","first-page":"e1002041","DOI":"10.1371\/journal.ppat.1002041","article-title":"Protective efficacy of serially up-ranked subdominant CD8+ T cell epitopes against virus challenges. Douek DC, editor","volume":"7","author":"Im","year":"2011","journal-title":"PLoS Pathog"},{"issue":"5","key":"10.1016\/j.vaccine.2020.05.042_b0235","doi-asserted-by":"crossref","first-page":"3339","DOI":"10.4049\/jimmunol.180.5.3339","article-title":"MHC Class II-associated invariant chain linkage of antigen dramatically improves cell-mediated immunity induced by adenovirus vaccines","volume":"180","author":"Holst","year":"2008","journal-title":"J Immunol"},{"issue":"6","key":"10.1016\/j.vaccine.2020.05.042_b0240","doi-asserted-by":"crossref","first-page":"e100538","DOI":"10.1371\/journal.pone.0100538","article-title":"Enhanced vaccine-induced CD8+ T cell responses to malaria antigen ME-TRAP by fusion to MHC class ii invariant chain","volume":"9","author":"Spencer","year":"2014","journal-title":"PLoS ONE"},{"key":"10.1016\/j.vaccine.2020.05.042_b0245","doi-asserted-by":"crossref","first-page":"1032","DOI":"10.3389\/fimmu.2018.01032","article-title":"Animal models to study hepatitis C virus infection","volume":"9","author":"Burm","year":"2018","journal-title":"Front Immunol"}],"container-title":["Vaccine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X20306873?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X20306873?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,2]],"date-time":"2025-10-02T10:44:56Z","timestamp":1759401896000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0264410X20306873"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,7]]},"references-count":49,"journal-issue":{"issue":"32","published-print":{"date-parts":[[2020,7]]}},"alternative-id":["S0264410X20306873"],"URL":"https:\/\/doi.org\/10.1016\/j.vaccine.2020.05.042","relation":{},"ISSN":["0264-410X"],"issn-type":[{"value":"0264-410X","type":"print"}],"subject":[],"published":{"date-parts":[[2020,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Viral vectored hepatitis C virus vaccines generate pan-genotypic T cell responses to conserved subdominant epitopes","name":"articletitle","label":"Article Title"},{"value":"Vaccine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.vaccine.2020.05.042","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}]}}